Source: Switzerland – Department of Home Affairs
Headline: Swissmedic receives second application for the authorisation of a coronavirus vaccine
The Swiss therapeutic products agency reviews another vaccine in the rolling submission procedure
At the end of last week the pharmaceutical company Pfizer submitted an application for the authorisation of a vaccine against the SARS-CoV-2 virus. The vaccine candidate is based on the mRNA technology of the biotech company BioNTech. Swissmedic is now reviewing the active substance BNT162b2 in a “rolling submission” procedure. Swissmedic is fast-tracking all applications connected with the COVID-19 pandemic, assigning extra staff to this task so that content checks and, in particular, user safety are not compromised.